Print this page
melanoma
-
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation.
Protocol: 082201Principal Investigator:
- Lara Hathout
Applicable Disease Sites: Prostate -
A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy.
Protocol: 082210Principal Investigator:
- Saum Ghodoussipour
Applicable Disease Sites: Urinary Bladder -
Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition.
Protocol: 082304Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Prostate -
A Randomized Trial of High-Risk Metachronous OligometastatIc Prostate Cancer with High-Risk Mutations Treated with Metastasis Directed Therapy and Niraparib/Abiraterone Acetate and Prednisone (KNIGHTS).
Protocol: 082405Principal Investigator:
- Matthew Deek
Applicable Disease Sites: Prostate -
A Phase 2 Trial of Durvalumab (MEDI4736) plus Monalizumab in Non-Muscle-Invasive Bladder Cancer.
Protocol: 082501Principal Investigator:
- Saum Ghodoussipour
Applicable Disease Sites: Urinary Bladder -
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator's Choice in HLAA*02:01-Positive Participants with Previously Treated Advanced Melanoma.
Protocol: 092203Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase I Study to Evaluate the Safety of Naltrexone and Propranolol in Combination with Standard of Care Ipilimumab and Nivolumab in Patients with Advanced Melanoma.
Protocol: 092302Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase 2 and Phase 3 Peri-Operative trial of Fianlimab and Cemiplimab Compared with Pembrolizumab in Patients with Resectable Stage III and IV Melanoma.
Protocol: 092303Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO).
Protocol: 092305Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2).
Protocol: 092401Principal Investigator:
- Vadim Koshenkov
Applicable Disease Sites: Soft Tissue -
A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab versus Relatlimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma.
Protocol: 092402Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors.
Protocol: 111904Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Other Female Genital
Other Male Genital -
A Phase 1, Multicenter, Open-Label, 2-Stage, Single-Arm Study to Evaluate the Safety and Tolerability of an Autologous Tumor-Infiltrating Lymphocytes (TIL) Regimen and Preliminary Antitumor Activity of TIL in Pediatric, Adolescent, and Young Adult Participants with Relapsed or Refractory Solid Tumors.
Protocol: 112309Applicable Disease Sites: Any Site
-
Facebook Intervention for Young Onset Melanoma Patients and Families.
Protocol: 131812Principal Investigator:
- Sharon Manne
Applicable Disease Sites: Melanoma, Skin -
Understanding Sun Protection and Skin Examination Practices Among Hispanics.
Protocol: 132111Principal Investigator:
- Carolyn J Heckman
Applicable Disease Sites: Melanoma, Skin -
A Digital Intervention to Improve Skin Self-Examination Among Melanoma Survivors.
Protocol: 132202Principal Investigator:
- Sharon Manne
Applicable Disease Sites: Melanoma, Skin